ABSTRACT
INTRODUCTION
Pre-eclampsia (PE) remains a leading cause of maternal and perinatal mortality and morbidity in both developed and developing countries 1 -3 . PE is thought to result from an imbalance between angiogenic factors, such as placental growth factor (PlGF), and antiangiogenic factors, such as soluble fms-like tyrosine kinase-1 (sFlt-1) 4 . Several studies have reported that the maternal serum concentration of PlGF is reduced, while that of sFlt-1 and the sFlt-1/PlGF ratio are increased, both at the time of and prior to, the clinical diagnosis of PE 5 -13 . Maternal serum concentrations of PlGF, but not those of sFlt-1, are altered from as early as 11 weeks' gestation in women who eventually develop PE 13, 14 . Moreover, maternal serum levels of PlGF, sFlt-1 and the sFlt-1/PlGF ratio could also have prognostic value 7,9 -11 . When the results of these studies were combined in a meta-analysis, the predictive accuracy of maternal serum PlGF and sFlt-1 levels measured before 30 weeks' gestation was too poor to be useful in clinical practice 15 . However, in a recent screening study, maternal serum PlGF and sFlt-1 levels measured at 30-33 weeks' gestation allowed detection of 100%, 76% and 62% of pregnancies with PE requiring delivery within 4, 6 and 8 weeks of the assessment, respectively, for a fixed false-positive rate of 5% 16 . Despite the fact that maternal serum levels of PlGF and sFlt-1 are affected by maternal characteristics, many screening studies have failed to take this into account 7 -12 . Furthermore, most studies were cross-sectional and focused on specific gestational age ranges, commonly 11-13, 20-24 or 30-33 weeks' gestation 16 -19 . Few studies, most of which were nested case-control studies, have investigated longitudinal changes in sFlt-1 and PlGF levels in women who eventually developed PE 20 -24 . The results of these studies are variable. Nevertheless, some have demonstrated that longitudinal changes are better predictors of PE than is measurement at a single time point during pregnancy and they appear to be more strongly associated with early-onset disease 21, 25 . Importantly, most of these longitudinal studies did not involve adjustment for maternal characteristics.
The aim of this study was to investigate longitudinal changes in maternal serum concentrations of sFlt-1 and PlGF, from the first trimester onward, in women identified as being at high risk following first-trimester screening and who subsequently developed PE or gestational hypertension (GH) or remained normotensive.
METHODS
At University College London Hospital, the risk of developing PE is assessed routinely at 11 + 0 to 13 + 6 weeks' gestation using a combination of maternal history, uterine artery Doppler mean pulsatility index, mean arterial pressure and serum pregnancy-associated plasma protein-A 26 . The present study took place between December 2009 and May 2012 and those women considered to be at high risk of early-onset PE were followed in a specialist hypertension clinic in which blood samples were collected every 4 weeks until delivery. Written informed consent was obtained from all women participating in the study which was approved by the London-Surrey Borders Research Ethics Committee. None of these pregnancies was complicated by aneuploidy or major structural abnormalities.
Maternal serum PlGF and sFlt-1 levels were measured in 234 women, with blood samples taken every 4 weeks until delivery. None of the samples was previously thawed and refrozen. Recorded patient characteristics included maternal age, racial origin (Caucasian, Afro-Caribbean, South Asian, East Asian or mixed), method of conception (spontaneous or assisted, requiring the use of ovulation-inducing drugs), cigarette smoking during pregnancy, history of chronic hypertension or pre-existing diabetes mellitus, history of PE in the mother of the patient, obstetric history including parity (parous or nulliparous if no previous pregnancies at or after 24 weeks) and previous pregnancy with PE. Maternal weight and height were also measured, and body mass index was calculated.
The scientist performing the assays for sample analysis was not aware of clinical data concerning the patient and was blinded to pregnancy outcome. Serum PlGF and sFlt-1 levels were measured in parallel, using an automated electrochemiluminescence immunoassay system (Cobas e411, Roche Diagnostics, Penzberg, Germany). The interassay coefficients of variation for low and high concentrations were 5.4% and 3.0% for PlGF and 3.0% and 3.2% for sFlt-1, respectively. The Cobas e411 analyzer PlGF assay has a detection range of 3-10 000 pg/mL and the sFlt-1 assay of 10-85 000 pg/mL.
Data on pregnancy outcomes were collected from hospital records. The obstetric records of women with pre-existing or pregnancy-associated hypertension were examined to determine if the condition was chronic hypertension, PE or GH. The diagnoses of PE and GH were made according to guidelines of the International Society for the Study of Hypertension in Pregnancy 27 . GH was defined as systolic blood pressure (BP) of ≥ 140 mmHg and/or diastolic BP of ≥ 90 mmHg on at least two occasions 4 h apart, developing after 20 weeks' gestation in a previously normotensive woman, in the absence of significant proteinuria. PE was defined as GH with proteinuria of ≥ 300 mg in 24 h or two readings of at least ++ on dipstick analysis of a midstream or catheter urine specimen, if 24-h collection was not available. PE superimposed on chronic hypertension was defined as significant proteinuria (as defined above) developing after 20 weeks' gestation in a woman with known chronic hypertension (history of hypertension before conception or presence of hypertension at the booking visit before 20 weeks' gestation in the absence of trophoblastic disease).
Statistical analysis
Maternal baseline characteristics were compared using the chi-square test or Fisher's exact test for categorical variables and the Kruskal-Wallis test for continuous variables; comparisons among different outcome groups were made using the Mann-Whitney U-test with post-hoc Bonferroni correction for multiple comparisons. Data are presented as median (interquartile range) for continuous variables and as n (%) for categorical variables.
The distribution of maternal plasma sFlt-1 and PlGF values were log 10 transformed. Analysis of repeat measurements with multilevel mixed-effects linear models (fixed effects and random effects) was performed. The fixed-effect component included up to third-order polynomial terms of gestational age, hypertensive disorders (PE or GH) and first-order interaction between gestational age and each hypertensive disorder. The random-effect component included the intercept and linear effects of gestational age. Repeat measurements at different weeks' gestation in the same woman constituted Level 1 and each individual constituted Level 2. The multilevel model was Table 1 Maternal characteristics, according to outcome group, in 234 pregnant women assessed for development of pre-eclampsia (PE) and gestational hypertension (GH) 
Data are given as median (interquartile range) or n (% compared to the one-level model by the likelihood ratio (LR) test. Prior to performing regression analysis, continuous variables were centered by subtracting the mean from each measured value (70 from maternal weight in kg, 164 from maternal height in cm and 32 from maternal age in years). The predictive accuracy of preterm PE using PlGF and sFlt-1 levels as well as the sFlt-1/PlGF ratio by a single measurement at 11-13 and 19-23 weeks' gestation, and by repeat measurements was determined by receiver-operating characteristics (ROC) curve analysis. The areas under the ROC curves (AUC) of sFlt-1, PlGF and sFlt-1/PlGF values were compared to assess their performance in the prediction of preterm PE.
The software programs MLwiN 2.28 (Centre for Multilevel Modelling, University of Bristol, Bristol, UK) 28 and IBM SPSS Statistics 20 (SPSS Inc., Chicago, IL, USA) were used for statistical analysis.
RESULTS
Both PlGF and sFlt-1 values were analyzed in a total of 1069 samples from 234 women, with a median of three (range, 1-8) samples per woman. Of the 234 pregnant women included, 172 remained normotensive, 18 developed GH, 22 developed PE requiring delivery after 37 weeks (term PE) and 22 developed PE requiring delivery at or before 37 weeks (preterm PE). Maternal characteristics of each outcome group are summarized in Table 1 . Median maternal height was significantly lower in women who developed term PE (P = 0.017). There were no significant differences in maternal age (P = 0.051), weight (P = 0.232), ethnicity (P = 0.260), parity (P = 0.907), smoking status (P = 0.531), chronic hypertension (P = 0.105) or mode of conception (P = 0.368) among the different outcome groups.
Maternal serum sFlt-1 levels decreased significantly with maternal weight (Table 2 ). Levels were significantly higher in women of Afro-Caribbean and East Asian racial origin and in those who underwent ovulation induction, but was not significantly affected by maternal age (P = 0.589), height (P = 0.596), smoking status (P = 0.864), history of PE (P = 0.196) or chronic hypertension (P = 0.830). A random-slope model provided a significantly better fit to the data than did a single-level model (LR = 516; degrees of freedom (df) = 3; P < 0.001) or a random-intercept model (LR = 122; df = 2; P < 0.001). In the normotensive group, there was a quadratic increase of log 10 sFlt-1 with gestational age (Table 2 and Figure 1 ). Maternal serum sFlt-1 levels decreased until 19 weeks' gestation and increased thereafter. In the preterm PE group, compared to the normotensive group, sFlt-1 levels were significantly increased from 15 weeks' gestation onward and the difference increased with gestational age (Table 2 and Figure 1b ). In the term PE and GH groups, maternal serum sFlt-1 levels did not differ significantly from those in the normotensive group (P = 0.044 and P = 0.999, respectively; Figures 1c and d) .
Maternal serum PlGF levels were significantly higher in women of Afro-Caribbean and South Asian racial origin but were not significantly affected by maternal age (P = 0.366), weight (P = 0.107), height (P = 0.317), smoking status (P = 0.261), mode of conception (P = 0.555), history of PE (P = 0.208) or chronic hypertension (P = 0.718). A random-slope model provided a significantly better fit to the data than did a single-level model (LR = 542; df = 3; P < 0.001) or a random-intercept model (LR = 152; df = 2; P < 0.001) ( Table 2 ). In the normotensive group, there was a quadratic association of log 10 PlGF with gestational age (Table 2 and Figure 2a ). PlGF levels increased until 28 weeks' gestation and decreased thereafter. In the preterm PE group, compared to the normotensive group, PlGF levels were significantly lower from 11 weeks' gestation onward and the difference increased significantly with gestational age (Table 2 and Figure 2b) . Similarly, in the term PE and GH groups, maternal serum PlGF levels were lower from 13 weeks' gestation and from 27 weeks' gestation onward, respectively, than in women who remained normotensive and the difference increased significantly with gestational age (Figures 2c and d) .
The maternal serum sFlt-1/PlGF ratio was significantly lower in parous women, with or without previous PE, but was not significantly affected by maternal age (P = 0.799), weight (P = 0.215), height (P = 0.729), racial origin (P = 0.196), smoking status (P = 0.480), mode of conception (P = 0.083) or chronic hypertension (P = 0.832). A random-slope model provided a significantly better fit to the data than did a single-level model (LR = 468; df = 3; P < 0.001) or a random-intercept model (LR = 183; df = 2; P < 0.05) ( Table 2 ). In the normotensive group, there was a quadratic association of log 10 sFlt-1/PlGF with gestational age (Table 2 and Figure 3a) . The maternal serum sFlt-1/PlGF ratio decreased until 26 weeks' gestation but increased thereafter. In the preterm PE group, compared to the normotensive group, the maternal serum sFlt-1/PlGF ratio was significantly higher from 11 weeks' gestation onward and the difference increased significantly with gestational age (Table 2 and Figure 3b) . Similarly, in the term PE and GH groups, the sFlt-1/PlGF ratio was significantly higher from 21 weeks' and 23 weeks' gestation onward, respectively, and the difference increased significantly with gestational age (Figures 3c and d) .
The performance of screening for preterm PE was not significantly improved by repeat measurements of PlGF levels, when compared to a single measurement obtained at 11-13 weeks (P = 0.348) or a single measurement at 19-22 weeks (P = 0.781), by repeat measurements of sFlt-1 levels, when compared to a single measurement at 11-13 weeks (P = 0.871) or a single measurement at 19-22 weeks (P = 0.093) or by repeat measurements of the sFlt-1/PlGF ratio, when compared to a single measurement at 11-13 weeks (P = 0.376) or a single measurement at 19-22 weeks (P = 0.084) (Table 3) . However, the study is likely to be underpowered to determine whether repeat measurements of sFlt-1 or PlGF levels are superior to a single measurement. A random-slope model provided a significantly better fit to the data than did a single-level model for sFlt-1 (LR = 516; df = 3; P < 0.001), PlGF (LR = 542; df = 3; P < 0.001) and sFlt-1/PlGF ratio (LR = 468; df = 3; P < 0.001).
DISCUSSION
This study demonstrates that, in normotensive pregnancies, there is a quadratic association between gestational age and maternal serum concentrations of sFlt-1 and PlGF and their ratio. Both sFlt-1 levels and the sFlt-1/PlGF ratio increase with gestational age, with a second-trimester trough (at 19 weeks for sFlt-1 and 26 weeks for the sFlt-1/PlGF ratio), whereas PlGF levels increase with advancing gestation, with a peak at 28 weeks and a decrease thereafter. In women with preterm PE, compared to normotensive controls, maternal serum levels of PlGF are significantly lower and the sFlt-1/PlGF ratio is significantly higher from 11 weeks' gestation onward, while sFlt-1 levels are significantly higher from 15 weeks' gestation onward. The difference in maternal serum levels of these biochemical markers between women who develop preterm PE, compared to those who remain normotensive, increases with gestation.
In women with term PE, compared to normotensive controls, maternal serum levels of PlGF are significantly lower and the sFlt-1/PlGF ratio is significantly higher from 13 weeks' and 21 weeks' gestation, respectively, and the difference increases with gestation. These changes are detected from 27 weeks' and 23 weeks' gestation, respectively, in women who develop GH. Again, these differences increase with gestation. Maternal serum levels of sFlt-1 were not significantly different from those in the normotensive group in women who developed term PE or GH.
This study has several strengths, including its prospective longitudinal design, the use of a well-defined methodology and the application of a robust statistical approach that takes into account not only the difference in marker levels in outcome groups but also the change throughout gestation. This approach is different from the calculation of trends with gestational age that are based on large numbers of cross-sectional and unrelated measurements. A limitation of the study is the relatively small number of cases.
PE is characterized by impairment in the physiological process of trophoblastic invasion of the maternal spiral arteries, resulting in persistence of high impedance in the uterine vessels 29 -31 . It is likely that the resulting hypoxia suppresses PlGF and upregulates sFlt-1 expression in trophoblast cells, leading to an exaggerated angiogenic/antiangiogenic imbalance 5, 32, 33 . Soluble sFlt-1 is a splice variant of vascular endothelial growth factor (VEGF) receptor-1 (Flt-1), while both VEGF and PlGF are key vascular endothelial growth factors in angiogenesis and vasculogenesis 34 . Circulating sFlt-1 can bind to PlGF and VEGF, effectively inhibiting their actions, hence its role as an antiangiogenic factor 35, 36 . Soluble sFlt-1 was found to be downregulated by the heme oxygenase (Hmox1)/carbon monoxide (CO) pathway 37 . This phenomenon might account for the protective effect of smoking against development of PE 37 . Moreover, statins induce heme oxygenase, and therefore suppress the release of sFlt-1 and induce PlGF 38, 39 . Ongoing studies are investigating the role of statins and Hmox1 activators as potential novel therapeutic agents for treating PE 37 -40 . Promising results were reported in a pilot study in which Thadhani et al. performed extracorporeal apheresis that resulted in lowering of sFlt-1 levels, reducing proteinuria, stabilizing BP and prolonging pregnancy without apparent adverse effects for mother and fetus 41 . Our finding that in normotensive pregnancies maternal serum levels of PlGF decrease with increasing gestational age and are higher in women of Afro-Caribbean and South Asian origin than in Caucasian women is compatible with results of previous screening studies 16 . Similarly, consistent with published evidence, maternal serum sFlt-1 levels increased with gestational age and were higher in women of Afro-Caribbean origin and women who conceived by assisted conception 16 . The incidence of PE in the study population was 18.8%, and that of GH was 7.7%. This is consistent with the fact that our study involved a population identified as being at high risk of PE following first-trimester screening.
Our findings in normotensive pregnancies, of a non-linear relationship between gestational age and maternal serum levels of PlGF and sFlt-1, as well as the sFlt1/PlGF ratio, are compatible with results of previous longitudinal studies 20, 23 . Similarly, our finding of reduced maternal serum PlGF levels in preterm PE before the clinical onset of PE, as early as 11 weeks' gestation, is consistent with both cross-sectional and longitudinal studies 13, 17, 20, 21, 23, 42, 43 . In term PE and GH, we found significantly lower maternal serum PlGF levels, from as early as 13 weeks' and 27 weeks' gestation, respectively 43 . In our study cohort, during the first trimester, maternal serum sFlt-1 levels were not significantly different in women who developed PE and those who remained normotensive. The levels were significantly different from 15 weeks' gestation onward in those who developed preterm PE and the difference increased with gestation. These findings are consistent with earlier studies 14, 17, 20, 22, 23, 42, 43 . Maternal sFlt-1 levels were not significantly different in women who later developed GH, an observation consistent with previous studies 43 . Finally, the maternal serum sFlt-1/PlGF ratio was significantly higher in women who later developed PE or GH, compared to women with normotensive pregnancies, and the difference increased with gestational age. It seems that using the ratio, as compared to the use of sFlt-1 levels alone, allows detection of the risk of preterm PE at an earlier gestational age. Furthermore, the ratio has useful predictive value for pregnancies destined to be complicated by term PE or GH, in which maternal serum sFlt-1 levels were not significantly different from those in normotensive pregnancies. These findings are also consistent with those of previous studies 17,23,42 -44 . It remains to be determined whether it is cost-effective to use the maternal serum sFlt-1/PlGF ratio rather than PlGF levels alone in the prediction of PE.
The difference in sFlt-1 and PlGF levels as well as the sFlt-1/PlGF ratio in pregnancies complicated by preterm PE and those that remained normotensive increased with gestation. This finding could have implications for the prediction of PE; measuring maternal serum sFlt-1 and PlGF levels during the second and third trimesters, as well as the first trimester, could potentially improve their predictive accuracy in diagnosing PE. Erez et al. reported an odds ratio (OR) of 3.9 for the increase in sFlt-1levels alone, and an OR of 4.3 for an increase in PlGF concentration less than the median 21 . Our results are in agreement with previous findings that changes in biochemical markers, when measured longitudinally, are better predictors of PE than measurement at a single time point during pregnancy 25 . In conclusion, this study described longitudinal changes in maternal serum levels of sFlt-1 and PlGF as well as the sFlt-1/PlGF ratio in women with high-risk pregnancies who developed PE or GH and those who remained normotensive. Repeat measurements of these biochemical markers are likely to be better predictors of PE than measurement at a single time point during pregnancy, as the differences between normotensive and complicated pregnancies increase with gestation. In screening for preterm PE, the maternal serum level of PlGF is a useful marker from the first trimester onward, while the sFlt-1 level has a predictive value from the second trimester onward. In term PE, maternal serum PlGF levels are reduced from the first trimester onward, while sFlt-1 levels are unlikely to be useful for prediction. The sFlt-1/PlGF ratio might provide added predictive value, compared to the use of a single marker. These results are likely to be useful in continuing efforts to improve the accuracy of predicting PE.
